# BioCryst Pharmaceuticals share price today (BioCryst Pharmaceuticals, Inc., BCRX)

> BioCryst Pharmaceuticals, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. BCRX · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/bcrx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $8.57 (+17.1% in a year)
- Revenue (Jun 2026): $218 M (+33.6% on a year ago)
- Profit (Jun 2026): $78.4 M (+1,441.7% on a year ago)
- Operating margin: 45.1% (+26.9 points on a year ago)
- ROE: −221%, FY25
- ROIC: 138.8%, against a 7.2% cost of capital: +131.6 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the BioCryst Pharmaceuticals share price today? BioCryst Pharmaceuticals, Inc.'s share price was $8.57 at the close on 3 November 2026. It has been moving sideways for 7 weeks. That is 2.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $10, and at that close it sat 54% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 10 years the share price moved +177% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does BioCryst Pharmaceuticals pay? BioCryst Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is BioCryst Pharmaceuticals on? BioCryst Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is BioCryst Pharmaceuticals profitable? BioCryst Pharmaceuticals, Inc. earned $78.4 M of net profit in the Jun 2026 quarter, +1,441.7% on the same quarter a year earlier. Full-year FY25 profit was $264 M. That is 35.9% of the quarter's revenue. The same quarter a year earlier earned $5.1 M. 7 of the last 12 reported quarters were loss-making. ## How much revenue does BioCryst Pharmaceuticals make, and is it growing? BioCryst Pharmaceuticals, Inc. reported $218 M of revenue in the Jun 2026 quarter, +33.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 53.6% a year on average. The last full year, FY25, came in at $875 M. The last four reported quarters add to $941 M. FY25 revenue was $875 M, +94.1% on the year before. Recent pace: the last four quarters grew +71.6% on average, against 53.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +68.7%, against +56.9% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does BioCryst Pharmaceuticals keep? BioCryst Pharmaceuticals, Inc.'s operating margin was 45.1% in the Jun 2026 quarter, 26.9 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −113.1% and 39.7%. The latest quarter is above every full year in that period. Across 5 years it has been between −113.1% and 39.7%, and FY25's 39.7% is the highest of them. Why the margin moved: operating margin changed +26.9 percentage points on the year while gross margin changed +2.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is BioCryst Pharmaceuticals' profit turning into cash? BioCryst Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $347 M of operating cash against $264 M of profit. After $2.5 M of spending on assets, $345 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does BioCryst Pharmaceuticals' cash go? BioCryst Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.8 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is BioCryst Pharmaceuticals' P/E ratio, and how does it compare with its own history? BioCryst Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values BioCryst Pharmaceuticals, Inc. at 2.5× its FY25 revenue of $875 M. The P/E comes back here once profit turns positive. ## Is the BioCryst Pharmaceuticals business getting better or worse? BioCryst Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does BioCryst Pharmaceuticals earn on its capital? BioCryst Pharmaceuticals, Inc. earned a ROE of −221% in FY25. Its return on capital used (ROIC) is 131.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 30.2% net margin and 1.70× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 30.2% net margin × 1.70× asset turnover × −4.32× leverage (assets divided by equity) ≈ −221.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 138.8% − 7.2% = +131.6 percentage points. The 7.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 138.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 105.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does BioCryst Pharmaceuticals have too much debt? BioCryst Pharmaceuticals, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −5.55 in FY21 to −4.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the BioCryst Pharmaceuticals shareholding pattern? 12.0% of BioCryst Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is BioCryst Pharmaceuticals from balance-sheet trouble? For BioCryst Pharmaceuticals, Inc., the Z-score is 0.52. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.52 is inside the danger zone, so the balance sheet is a real risk. ## How does BioCryst Pharmaceuticals rank in its industry? 58.9 out of 100, rank 7 of 28 in Drug Manufacturers - Specialty & Generic, with 64% of the evidence available. BioCryst Pharmaceuticals, Inc. scores 58.9 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 7. Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. The four parts add up to the total exactly: 25.3 + 18.1 + 11 + 4.5 = 58.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is BioCryst Pharmaceuticals compared with? BioCryst Pharmaceuticals ranks 7 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 58.9 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. BioCryst Pharmaceuticals, Inc. this page BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to BioCryst Pharmaceuticals in size? BioCryst Pharmaceuticals is the 22nd largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: HUTCHMED (China), Prestige Consumer Healthcare Inc. and Trulieve Cannabis Corp. Just below it: Perrigo Company plc, Xeris Biopharma Holdings, Inc. and Supernus Pharmaceuticals, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) $2.4 billion
2. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) $2.3 billion
3. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) $2.2 billion
4. BioCryst Pharmaceuticals, Inc. $2.2 billion
5. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) $2.2 billion
6. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) $1.9 billion
7. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) $1.6 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [DoubleVerify Holdings, Inc.](https://www.sectoralpha.in/us/stocks/dv) $2.1 billion · Advertising Agencies
2. [National Energy Services Reunited Corp.](https://www.sectoralpha.in/us/stocks/nesr) $2.1 billion · Oil & Gas Equipment & Services
3. BioCryst Pharmaceuticals, Inc. $2.1 billion
4. [Driven Brands Holdings Inc.](https://www.sectoralpha.in/us/stocks/drvn) $2.1 billion · Auto & Truck Dealerships
5. [Amplitude, Inc.](https://www.sectoralpha.in/us/stocks/ampl) $2.1 billion · Software - Application

## What else do people ask about BioCryst Pharmaceuticals? ### What were BioCryst Pharmaceuticals's latest quarterly results? BioCryst Pharmaceuticals, Inc. reported revenue of $218 M and net profit of $78.4 M for the Jun 2026 quarter. Revenue rose 33.6% and profit rose 1,441.7% compared with a year earlier. Earnings per share were $0.30. The operating margin was 45.1%, 26.9 percentage points higher than a year earlier (as of 3 November 2026). ### What is BioCryst Pharmaceuticals's market cap? BioCryst Pharmaceuticals, Inc.'s market capitalisation is $2.2 B at a stock price of $8.57. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is BioCryst Pharmaceuticals performing? BioCryst Pharmaceuticals, Inc.'s share price has been moving sideways for 7 weeks. In its latest quarter, revenue rose 33.6% and profit rose 1,441.7% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running (as of 3 November 2026). ### Will BioCryst Pharmaceuticals's stock price go up? This page does not forecast BioCryst Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $8.57, and it has been moving sideways for 7 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is BioCryst Pharmaceuticals in its business cycle? BioCryst Pharmaceuticals, Inc.'s FY25 operating margin was 39.7%, against a 5-year range of −113.1% to 39.7%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 45.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the BioCryst Pharmaceuticals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is BioCryst Pharmaceuticals a stock worth studying right now? What the numbers show: BioCryst Pharmaceuticals, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.